Janus Henderson Group PLC Cuts Stock Holdings in Encompass Health Co. (NYSE:EHC)

Janus Henderson Group PLC lessened its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 31.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,078,888 shares of the company's stock after selling 498,831 shares during the quarter. Janus Henderson Group PLC owned approximately 1.07% of Encompass Health worth $99,598,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Encompass Health by 87.8% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after purchasing an additional 137 shares during the last quarter. Colonial Trust Co SC acquired a new position in Encompass Health during the 4th quarter valued at approximately $29,000. Transce3nd LLC bought a new position in Encompass Health during the 4th quarter worth $40,000. CBIZ Investment Advisory Services LLC increased its position in Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after buying an additional 127 shares during the period. Finally, Tompkins Financial Corp bought a new stake in Encompass Health in the fourth quarter valued at $46,000. Institutional investors own 97.25% of the company's stock.

Encompass Health Stock Up 1.0%

Shares of EHC stock traded up $1.17 during trading hours on Friday, hitting $120.94. 904,433 shares of the company were exchanged, compared to its average volume of 693,191. The company has a market capitalization of $12.19 billion, a PE ratio of 27.12, a PEG ratio of 2.31 and a beta of 0.91. The business has a 50 day moving average of $104.95 and a two-hundred day moving average of $100.60. Encompass Health Co. has a 52 week low of $82.74 and a 52 week high of $122.25. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the firm posted $1.12 EPS. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. Analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.56%. Encompass Health's dividend payout ratio is currently 14.05%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on EHC shares. UBS Group lifted their price target on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. StockNews.com upgraded shares of Encompass Health from a "hold" rating to a "buy" rating in a research report on Sunday, May 11th. KeyCorp boosted their target price on shares of Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Barclays raised their target price on shares of Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Encompass Health presently has an average rating of "Buy" and an average target price of $120.86.

Insider Activity at Encompass Health

In other news, insider Elissa Joy Charbonneau sold 4,279 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the sale, the insider now directly owns 11,958 shares of the company's stock, valued at $1,394,422.38. This represents a 26.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the transaction, the executive vice president now directly owns 79,710 shares in the company, valued at approximately $9,149,910.90. This represents a 11.15% decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by company insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.